Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arbutus Biopharma Corp ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.


NDAQ:ABUS - Post by User

Bullboard Posts
Post by seeingeyeon Jan 18, 2012 5:14pm
352 Views
Post# 19419187

ALNY counter suit

ALNY counter suit

Counter suit is pretty much a standard ploy used by legal eagles in this type of case.Not that this means there is no merit as this will be detemined by a judge as to whether it is allowed to proceed.

My guess(speculation on my part)is that they hope to lessen the potential size of any award given to TKM if they cannot present a successful defence against TKM's claim.

Interesting points to note are the web of connections of ALNY and the sharing of teck with various companies

Anylam is defending the Isis claim and is a partner with them in Regulus theraputics.Isis also has strategic partnership with GSK-Glaxco Smith Klien.

Makes you wonder to whom the pilfering of TKM teck would advantage and what if any incentives were given to those that took it from TKM without consent or knowledge of Tekmira.

Time will tell whose Lily white and who or whom gets the rope.Until then its innocent until proven guilty!!

Bullboard Posts